Risk stratification in diabetic kidney disease is challenging. Identifying nodular diabetic nephropathy (NDN), the most specific histological feature of diabetic nephropathy (DN), associated with poor prognosis, currently requires kidney biopsy. We aimed to identify urinary peptide biomarkers distinguishing NDN from other chronic kidney disease etiologies in diabetes (nNDN). In this case-control study, urinary peptide profiles from biopsy-proven DN patients (43 NDN, 38 nNDN) were analyzed using capillary electrophoresis-mass spectrometry. Real patient data were combined with synthetic datasets generated using a Gaussian copula approach and divided into discovery and validation cohorts. Differential peptides were identified by Wilcoxon testing with Benjamini-Hochberg correction, and combined into a support vector machine model. In the discovery cohort, 207 peptides were significantly altered. NDN was characterized by reduced collagen fragments and increased fibrinogen, apolipoprotein A-IV, and α1-antitrypsin peptides. The 99-peptide classifier (NDN99) discriminated NDN from nNDN with an AUC of 0.87 (combined validation) and 0.79 (real-patient validation). NDN99 predicted major adverse kidney events (MAKE; death, kidney failure, or 40% eGFR loss), and outperformed histology (HR = 2.9, p = 0.0006 vs HR = 1.9, p = 0.04). Urinary peptide signatures enable non-invasive discrimination of NDN and predict MAKE, potentially complementing kidney biopsy for subtype identification and risk stratification in DN.
Complement activation has been implicated in many kidney diseases, but it remains unclear whether urinary complement-derived peptides reflect kidney function beyond albuminuria and predict disease progression. We analyzed mass spectrometry-based urinary peptidomics data from 10,939 individuals with chronic kidney disease and healthy controls. Fifty-eight complement-derived peptides were identified, predominantly from complement factor B (CFB) and C3. Of these, fifty-two were significantly related to estimated glomerular filtration rate (eGFR) independently of albuminuria, mostly inversely. Several C3- and CFB-derived peptides were also associated with specific kidney disease etiologies. In a longitudinal analysis of 3964 individuals (median follow-up 2.91 years), 18 of these peptides were significantly related to a major adverse kidney event (MAKE, defined as ≥40% eGFR decline, end-stage kidney disease or death) after adjustment for clinical covariates, indicating prognostic information beyond traditional risk markers. In the independent test cohort, combining these peptides in a machine learning-based model and adding the resulting risk score to clinical parameters significantly improved MAKE prediction (AUC 0.801 vs. 0.778, p = 0.031). Thus, urinary complement-derived peptides provide independent and clinically relevant information on kidney function and disease progression, supporting their potential value in the identification of high-risk patients and guiding more personalized therapy.